IRVINE, Calif. – August 16, 2018 – AIVITA Biomedical, a biotech company specializing in innovative stem cell applications, announced today the addition of two senior members to its staff. Scott Burell joins the company as Chief Financial Officer and Kevin Green joins as Vice President of Business Development. The hires come at the close of AIVITA’s $15 million Series B round and as the Company develops its clinical and commercial offerings.

Scott Burell joins AIVITA as Chief Financial Officer with more than 25 years of corporate finance experience ranging from M&A to strategic management, operational management, financial reporting and compliance. He has served in biotech, healthcare and high-tech industries. Prior to joining AIVITA, Scott served as Chief Financial Officer of CombiMatrix Corporation, overseeing the company’s sale.

Kevin Green joins AIVITA as Vice President of Business Development, bringing with him more than a decade of experience in the dermatology and aesthetics industries. Kevin previously served as Senior Director of Business Development at Allergan for 10 years, leading over sixty diligence teams and completed over twenty transactions, including the second largest transaction in Allergan history with the $2.1 billion Kythera acquisition.

“Mr. Burell and Mr. Green bring decades of B2B, corporate finance and capital raising experience to AIVITA”, said Dr. Hans S. Keirstead, AIVITA’s Chairman and CEO. “These appointments reflect our plans for further capitalization via investment and partnership.”

Additional hires have been made to support the launch of a second Phase 2 clinical trial in AIVITA’s ROOT OF CANCER program. On the heels of its recently launched Phase 2 clinical trial for ovarian cancer, AIVITA will soon be recruiting patients for a Phase 2 clinical trial in glioblastoma. The Company has also made key hires in support of its ROOT OF SKIN^TM and ROOT OF SKIN^TM MD skincare lines, which introduced an all-new proprietary actives complex containing the natural ingredients of skin stem cells. All proceeds from the sale of AIVITA’s skin care products support the treatment of women with ovarian cancer.

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial line of skin care products and therapeutic pipeline.

###